Analysis reveals 36% of cases in which clinicians’ treatment plan differed from HIV and HCV guidelines
Reston, Virginia - October 3, 2019 - Many healthcare providers showed discordance from guideline recommendations in their first-line treatment selection for patients coinfected with HIV and hepatitis C virus (HCV), according to an analysis of data from an online treatment decision support tool developed by Clinical Care Options (CCO) during the past year.
The online tool allows users to define a patient case scenario using variables, such as current HIV therapy, HCV genotype, and liver histology, and receive instant recommendations from published guidelines. In more than one third of the 972 cases entered into the online tool between August 2018 and August 2019, users selected treatments that were inconsistent with guideline recommendations. Key areas of inconsistency involved user choices that were suboptimal due to drug–drug interactions, specific HCV genotype or HIV drug resistance, or the patient’s renal function or HLA-B*5701 status.
“In many cases where learners initially selected an option that differed from the guidelines, they indicated that they would change their treatment plan to match the guidelines after using the tool,” said Edward King, Executive Vice President of CCO. “Decision support tools such as this may improve outcomes for people coinfected with HIV and hepatitis C by helping healthcare providers to make optimal treatment choices.”
The results were presented October 3 at IDWeek 2019 in Washington, DC, and can be reviewed at https://www.clinicaloptions.com/publications/2019/10_2019_hcvhivcoinfection.
About Clinical Care Options
Clinical Care Options, LLC, is a global leader in the development of innovative educational programs and technology platforms. CCO’s team has been a pioneer in the creation of continuing education and decision support resources for healthcare professionals both in the United States and around the world for more than 2 decades. For more information, visit clinicaloptions.com.